Pharma Business - October 25, 2016
NeuroVive completes closure of Lyon subsidiary
NeuroVive Pharmaceutical has completed the closure of its dormant subsidiary in Lyon, France. The closure of the subsidiary NeuroVive France SARL is a natural consequence of the company’s previously communicated decision that it will not pursue development of CicloMulsion. Accordingly, all agreements related to the research partnership with Hospices Civils de Lyon (HCL) and Professor […]
Agreement - October 24, 2016
NeuroVive and Arbutus sign termination agreement
NeuroVive Pharmaceutical has announced that the license agreement with Arbutus Biopharma (formerly OnCore Biopharma) has been terminated and all rights to the NVP018 compound have been reverted back to NeuroVive. The agreement, signed in 2014, was related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of Hepatitis B viral infection. In its […]
In a new job - March 15, 2016
New CEO of NeuroVive
NeuroVive’s board of directors has appointed Erik Kinnman, who has extensive industry and research experience and has held a number of senior leadership positions in companies such as AstraZeneca and Sobi, as the new CEO of the company. He assumed the role on March 14. “The NeuroVive Board and I are confident that Erik Kinnman […]
Acquisition - January 14, 2016
NeuroVive buys stake in Isomerase Therapeutics
NeuroVive Pharmaceutical has made a partial acquisition of British company Isomerase Therapeutics with the overall goal to strengthen the partnership and accelerate NeuroVive’s research and development program. The acquisition aims to further enhance the collaboration and to ensure that NeuroVive’s projects remain a key priority for Isomerase. Furthermore, the partnership will support the discovery of new […]
Agreement - September 9, 2014
NeuroVive signs major agreement
The Swedish mitochondrial medicine company has signed an exclusive agreement worth USD 150 million with OnCore BioPharma. The agreement regards outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection. NeuroVive states that deal can give the company in total USD150 million in conditional milestone payments plus royalties on future drug sales. “After extensive discussions with a […]
Collaboration - March 25, 2014
Neurovive collaborates with A1M Pharma
NeuroVive Pharmaceutical AB and A1M Pharma AB have announced that the two companies are initiating a research collaboration in mitochondrial medicine. Initially, the purpose of the collaboration is to utilize the companies’ complementary scientific platforms within the framework of ongoing research projects. The companies will evaluate results achieved to date, then explore the potential for […]
